High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for relapsing-remitting multiple sclerosis (HALT-MS): a 3-year interim report.

Publication Type:

Journal Article


JAMA neurology, Volume 72, Issue 2, p.159-69 (2015)


Adult, Combined Modality Therapy, DISEASE PROGRESSION, Disease-Free Survival, Female, Follow-Up Studies, hematopoietic stem cell transplantation, Humans, Immunosuppressive Agents, Magnetic Resonance Imaging, Male, Middle Aged, Multiple Sclerosis, Relapsing-Remitting, Transplantation, Autologous, Treatment Outcome


Most patients with relapsing-remitting (RR) multiple sclerosis (MS) who receive approved disease-modifying therapies experience breakthrough disease and accumulate neurologic disability. High-dose immunosuppressive therapy (HDIT) with autologous hematopoietic cell transplant (HCT) may, in contrast, induce sustained remissions in early MS.